Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.

The Biochemical journal - 30 Sept 2022

Warren Hannah R, Ross Sarah J, Smith Paul D, Coulson Judy M, Prior Ian A

Abstract excerpt

Approximately 15% of all cancer patients harbor mutated KRAS. Direct inhibitors of KRAS have now been generated and are beginning to make progress through clinical trials. These include a suite of inhibitors targeting the KRASG12C mutation commonly found in lung cancer. We investigated emergent resistance to representative examples of different classes of Ras targeted therapies. They all exhibited rapid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Neoplasms
Share to Mutation
Share to Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 36065754
DOI: 10.1042/BCJ20220440
PMCID: PMC9555794

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.PMID 36065754Read ↗

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read ↗

Combinatorial strategies to target RAS-driven cancers.Semantic proximity Read ↗

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read ↗

Overcoming KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.Semantic proximity Read ↗

Identification of drug resistance mechanisms induced in response to KRAS therapeuticsSemantic proximity Read ↗

"Undruggable KRAS": druggable after all.Semantic proximity Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Semantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.